3 not yet recruiting, 1 completed, 1 recruiting, 1 unknown. 4 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 3, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow AG regimen: new trials by email Literature Review of AG regimen trials Research Report on AG regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer IBI343 - Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Not yet recruiting | Zhejiang University | 40 | 2026-02-01 | 2026-02-17 |
| Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer Nimotuzumab, AG regimen, Placebo - Pancreatic Cancer, Adult | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 156 | 2025-12-10 | 2025-12-11 |
| LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study Low-dose Radiotherapy, Pucotenlimab, AG regimen - Pancreatic Cancer, PD-L1 | Phase 1 / Phase 2 | Recruiting | Zhejiang Provincial People's Hospital | 10 | 2025-09-30 | 2026-01-26 |
| AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer AG regimen, Nimotuzumab - Pancreatic Cancer, Adult | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 48 | 2025-04-21 | 2025-04-22 |
| AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer Nab paclitaxel plus gemcitabine, mFOLFIRINOX - Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Unknown | Fudan University | 300 | 2021-09-01 | 2022-01-28 |
| Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer AG regimen, mFolfirinox - Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy | Phase 3 | Completed | Second Affiliated Hospital, Zhejiang University, School of Medicine | 324 | 2018-10-20 | 2025-05-13 |
Pancreatic Neoplasms (3) · Pancreatic cancer, adult (2)
Fudan University (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Zhejiang Provincial People's Hospital (1) · Zhejiang University (1)
China (5)
Chunyi Hao (1) · Kuirong Jiang, MD (1) · Tingbo Liang, MD PhD (1) · Xian-Jun Yu, MD, PhD (1)